Ph.D. University of California, Berkeley
1. Antibody engineering: We are engineering and investigating bispecific antibodies to deliver nanomedicines into cancer cells for improved anticancer selectivity and efficacy.
2. Nanomedicine: New approaches to stably load and retain hydrophobic drugs in liposomal nanocarriers are under development.
3. Directed molecular evolution: We perform directed molecular evolution of human enzymes for antibody-directed enzyme prodrug therapy.
4. Prodrug therapy: Anticancer prodrugs that are selectively activated in the tumor microenvironment are under investigation to improve the selectivity and therapeutic efficacy of cancer treatment.
5. Anti-PEG antibodies: We develop antibodies to assay PEGylated drugs in human serum and are extending these studies to investigating the impact of pre-existing and induced anti-PEG antibodies on the therapeutic efficacy and safety of PEGylated medicines.
Interactions between nanoparticle corona proteins and the immune systemCurrent Opinion in Biotechnology, Oct 16, 2023
Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated NanomedicinesACS Nano, Mar 16, 2023